Relay's Zovegalisib Shrinks Vascular Malformations in Mid-Stage Trial, 60% Response Rate
RLAY has more than doubled off its 52-week low of $2.75.
Summary
Relay Therapeutics announced positive mid-stage trial results for its experimental treatment, zovegalisib, in patients with rare vascular disorders. The data showed that zovegalisib reduced lesion size by at least 20% in approximately 60% of patients at 12 weeks, with nearly all patients showing some reduction and remaining on treatment. The treatment also demonstrated a favorable tolerability profile, with no discontinuations due to side effects. This significant clinical advancement builds on the recent FDA Breakthrough Therapy designation for zovegalisib for PIK, further de-risking the drug and expanding its potential in a new indication. These strong efficacy and safety results are highly material for Relay Therapeutics and could lead to a substantial re-rating of the stock as it progresses towards later-stage development and potential regulatory filings.
At the time of this announcement, RLAY was trading at $12.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $2.75 to $17.32. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.